(S)-1-(benzo[d][1,3]dioxol-5-yl)-N-(1-phenyl-2-(pyrrolidin-1yl)ethyl)cyclopropanecarboxamide | 1356547-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: (S)-1-(benzo[d][1,3]dioxol-5-yl)-N-(1-phenyl-2-(pyrrolidin-1yl)ethyl)cyclopropanecarboxamide
• 英文别名: 1-(1,3-benzodioxol-5-yl)-N-[(1S)-1-phenyl-2-pyrrolidin-1-ylethyl]cyclopropane-1-carboxamide
• CAS: 1356547-83-5
• 化学式: C₂₃H₂₆N₂O₃
• 分子量: 378.471
• InChiKey: RWWHBDLJPIOBKF-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• KAPPA OPIOID RECEPTOR AGONISTS
  申请人：Sasmal Pradip Kumar

  公开号：US20130303525A1

  公开（公告）日：2013-11-14

  The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
• US9303027B2
  申请人：——

  公开号：US9303027B2

  公开（公告）日：2016-04-05
• [EN] KAPPA OPIOID RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS OPIOÏDES KAPPA
  申请人：REDDYS LAB LTD DR

  公开号：WO2012012410A2

  公开（公告）日：2012-01-26

  The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, Rls R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.